Slowing the emptying of the stomach, which further limits blood sugar spikes and helps people to feel fuller for longer
The results were consistent: Trunk fat reduction: Tesamorelin-treated patients showed statistically significant reductions in trunk fat versus placebo at 26 weeks.[1] VAT reduction: Using cross-sectional CT imaging, tesamorelin produced approximately 1520% reductions in visceral adipose tissue compared to placebo.[1,2] Triglyceride improvement: Alongside fat reduction, tesamorelin improved triglyceride levels a key marker in metabolic syndrome.[2] Tesamorelin IGF-1 elevation: Treatment reliably elevated IGF-1 levels toward age-appropriate norms, confirming successful GH-axis stimulation.[1] These reductions occurred without dietary caloric restriction being mandated
[DOI] [PubMed] [Google Scholar] 17.Wasserman RH
Empowering Individuals, Organizations, and Healthcare Providers Since 2019
Older weight-loss medications achieve approximately five percent reduction in body weight over placebo, whereas these new GLP-1 agonists, like Ozempic, produce about triple the effect, about 15 percent
As interest grows in the effects of GLP-1based therapies beyond diabetes and obesity, questions are emerging about their potential impact on migraine
